Recent News

• 08.12.2025 - AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
• 08.12.2025 - AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
• 08.12.2025 - AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
• 08.12.2025 - AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
• 07.23.2025 - AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
• 07.23.2025 - AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
• 06.30.2025 - AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
• 06.30.2025 - AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

Recent Filings

• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.20.2025 - 8-K Current report
• 06.18.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2025 - EX-99.1 EX-99.1
• 06.11.2025 - 8-K Current report
• 06.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.03.2025 - 4 Statement of changes in beneficial ownership of securities